Navigation Links
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
Date:10/15/2007

was an international, multi-center, randomized, double-blind, placebo-controlled trial of patients naive to Lamictal, 13 years of age or older who were experiencing eight or more partial seizures during the eight- week baseline period despite taking a stable regimen of one or two antiepileptic drugs (AEDs). Two hundred and thirty-nine patients were randomized to receive either once-daily Lamictal XR or placebo (118 Lamictal XR, 121 placebo). The 19-week treatment period of the study consisted of a seven-week Escalation Phase and a 12-week Maintenance Phase.

The study's primary endpoint was median percent reduction from baseline in partial seizure frequency. Study results showed that Lamictal XR significantly reduced partial seizures by 46.1 percent, compared to 24.2 percent with placebo over the entire 19-week treatment period (P=0.0004). The study also showed significant overall reduction in seizure frequency with Lamictal XR in both the Escalation and Maintenance treatment phases of the study (P=0.028 and P=0.0001, respectively).

The percentage of patients who achieved a .50 percent reduction in partial seizure frequency during the 19-week treatment phase of the study was also significantly higher in the Lamictal XR group compared to placebo (42.2 percent versus 24.2 percent). In addition, the time to achieve and maintain a .50 percent reduction in partial onset seizure frequency was significantly shorter for the group treated with Lamictal XR compared to placebo. Statistical significance was evident at Day 18 and was maintained throughout the 19-week treatment phase of the study.

The median percent reduction from baseline in weekly frequency of secondarily generalized seizures was also significantly higher in patients receiving Lamictal XR compared to placebo (55.2 percent vs. 3.2 percent). Similar results were observed for the escalation and maintenance phases of the study.

The percentage of patients with at least one adverse event during
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  Syneron Medical Ltd. (NASDAQ: ELOS ), a ... the three month period ended June 30, 2015. ... Highlights: , Revenue of $73.5 million, ... North American product sales grew 45% year-over-year. , International ... 14% product growth in the EMEA region and 25% product ...
(Date:8/4/2015)... , Aug. 4, 2015  Ironshore Pharmaceuticals ... with Restore Health, a company specializing in personalized ... double-blind clinical trial, designed to evaluate the safety ... development to treat Attention-deficit/hyperactivity disorder (ADHD). This is ... Restore Health originally partnered with Ironshore in ...
(Date:8/3/2015)... Aug. 4, 2015   The Intellectual Property ... world,s leading provider of intelligent information for businesses ... 2015 CMR Pharmaceutical R&D Factbook , the biopharmaceutical ... concerns around declines in R&D, the analysis identifies ... trillion milestone and forecasts sales to reach $1.3 ...
Breaking Medicine Technology:Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Pharma Sales to Grow Beyond $1 Trillion 2
... March 31, 2011 Reportlinker.com announces that a new ... Cardiac Marker Diagnostic Testing Markets ... purpose of this TriMark Publications report is to describe ... (IVD) market devoted to cardiac marker testing. This study ...
... Virtual Radiologic (vRad), a technology-enabled national radiology ... Sales & Customer Service. vRad® Results (SM) is a ... that provides secure access to images and radiology reports ... devices and the Internet. vRad received the award in ...
Cached Medicine Technology:Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 2Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 3Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 4Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 5Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 6Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 7Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 8Virtual Radiologic Wins Stevie® Award for Improving Patient Care through Mobile Technology 2
(Date:8/4/2015)... ... August 04, 2015 , ... ... brings an automatic end to driving, says the August 2015 Harvard Health Letter. ... okay to drive. It requires an individual assessment of skills," says Lissa Kapust, ...
(Date:8/4/2015)... NY (PRWEB) , ... August 04, 2015 , ... ... mortgage lender specializing in healthcare finance, announced the closing of a $118 million ... two campus health system located in Smithfield and Clayton, North Carolina. JHSC ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... Process Chemistry and Scale-up Online Seminar featuring researchers from Lubrizol, Pfizer, and ... at 1:00 PM EDT. , Process development project timelines often require informed decisions ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Updated enrollment ... (AIS) in-house research team, can now be accessed at http://www.AISHealth.com . The data ... Directory of Health Plans: 2015, the tables and charts on the website’s “Data” section ...
(Date:8/4/2015)... Ill. (PRWEB) , ... August 04, 2015 , ... ... and the specialty in which the physician is board-certified is increasingly influential in ... for Dermatologic Surgery. , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures ...
Breaking Medicine News(10 mins):Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... driving the trend, study says , , TUESDAY, Nov. 6 ... disease is on the rise, and diabetes and high blood ... the increase, a new study suggests. , "When we looked ... was more common than previously appreciated," said lead researcher Dr. ...
... ... http://www.amerathonclub.com Encourages Consistent Exercise for Individuals and ... Families -, PITTSBURGH, ... while maintaining a healthy,lifestyle. The Amerathon Club has introduced a new online and interactive,total ...
... Healthcare NHS Trust Implements Ericom,s Alternative to Citrix ... ... 6 ,Ericom(R) Software, a leading provider of Enterprise-Wide Application,Access solutions, ... selected PowerTerm(R) WebConnect Enterprise edition to provide,employees with secure access ...
... is available in Spanish . , ANN ARBOR, Mich. ... the fact that nearly one in five American women still smokes, ... possible reasons for the stubborn persistence of smoking, fear of weight ... University of Michigan Health System researcher who has devoted much of ...
... work together to maintain addiction, study suggests , , TUESDAY, ... know all too well, drinking and smoking tend to ... might be so. , It,s well known that, "The ... someone continues smoking," noted lead researcher Thomas J. Gould, ...
... for State,s Second Site, ATLANTA, Nov. 6 ... has named Atlanta Medical Center as Georgia,s second,hospital ... March,of Dimes NICU Family Support(R) provides information and ... newborns being cared for in,a Neonatal Intensive Care ...
Cached Medicine News:Health News:Kidney Disease Increasing in U.S. 2Health News:Kidney Disease Increasing in U.S. 3Health News:Innovative Amerathon Club Website 'Virtual' Journey to Good Health 2Health News:UK Government (NHS) Selects Ericom to Enable Secure Application Access for its Medical and Administrative Staff 2Health News:Is fear of gaining weight keeping many women from trying to quit smoking? 2Health News:Is fear of gaining weight keeping many women from trying to quit smoking? 3Health News:Is fear of gaining weight keeping many women from trying to quit smoking? 4Health News:Nicotine Plus Alcohol May Be Tough to Beat 2Health News:Nicotine Plus Alcohol May Be Tough to Beat 3Health News:Georgia Receives Second March of Dimes NICU Family Support(R) Project 2Health News:Georgia Receives Second March of Dimes NICU Family Support(R) Project 3
VersaStep™ Reposable Sterilization Trays....
... device is comprised of the following components. ... port are also packaged in the following ... with 12 mm Step™ cannula assembly and ... mm locking cone with 10/12 mm Reposable ...
... components are supplied sterile. , ,The Step™ ... sterile in 2/3, 5, 7/8, 10 and 12 ... They are used in conjunction with the Step™ ... Expandable Sleeve. The 5, 7/8, 10 and 12 ...
... VERSAPORT™ PLUS V2 RT single-use obturator has a ... , ,The Auto Suture™ VERSAPORT™ PLUS V2 ... 5-12, 11 mm and 12 mm diameters with ... and 5 mm short single-use obturators are not ...
Medicine Products: